Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Aljumaily · SciRah

Researcher profile · Semantic Scholar

R. Aljumaily

Share profile

R. Aljumaily — researcher profile on SciRah

h-index: 22
Works: 132
Citations: 2,998

Most-cited papers

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
Ziming Wang, Ethan G. Aguilar, Jesus I. Luna, C. Dunai +29 more
2018Nature Medicine803 citations Open access
Semantic Scholar
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
J. Weiss, T. Csőszi, M. Maglakelidze, R. Hoyer +26 more
2019Annals of Oncology154 citations Open access
Semantic Scholar
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
Juanita S. Lopez, T. Powles, F. Braiteh, L. Siu +76 more
2025Nature Medicine104 citations Open access
Semantic Scholar
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study
L. Hart, R. Ferrarotto, Z. Andrić, J. Beck +11 more
2020Advances in Therapy100 citations Open access
Semantic Scholar
Pegilodecakin Combined With Pembrolizumab or Nivolumab for Patients With Advanced Solid Tumours (IVY): A Multicentre, Open-Label, Phase 1b Trial
A. Naing, D. Wong, J. Infante, W. Korn +17 more
2019The Lancet Oncology98 citations Open access
Semantic Scholar
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors
A. Jimeno, K. Moore, M. Gordon, R. Chugh +7 more
2018Investigational new drugs78 citations
Semantic Scholar
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
A. Apolo, J. Ellerton, J. Infante, M. Agrawal +14 more
2020Journal for ImmunoTherapy of Cancer73 citations Open access
Semantic Scholar
Pulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic challenges, and diagnosis and management strategies.
T. Sen, Yosuke Dotsu, Virginia Corbett, Sonam Puri +8 more
2025The Lancet Oncology48 citations
Semantic Scholar
Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
A. Balmanoukian, J. Infante, R. Aljumaily, A. Naing +13 more
2020Clinical Cancer Research39 citations Open access
Semantic Scholar
Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors
Juanita Lopez, R. Camidge, M. Iafolla, S. Rottey +38 more
2020Bioinformatics, Convergence Science, and Systems Biology39 citations
Semantic Scholar
Pegilodecakin as monotherapy or in combination with anti‐PD‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study
N. Tannir, K. Papadopoulos, D. Wong, R. Aljumaily +7 more
2021International Journal of Cancer33 citations Open access
Semantic Scholar
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers
K. Jhaveri, Matthew T. Chang, D. Juric, C. Saura +17 more
2020Clinical Cancer Research32 citations Open access
Semantic Scholar
Do proton pump inhibitors modulate the efficacy of anti-PD-1/PD-L1 therapy? A retrospective study
S. Mukherjee, S. Ibrahimi, Bilal Khalid, Darwin Roman +2 more
2019Journal of Oncology Pharmacy Practice28 citations
Semantic Scholar
728O Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors
O. Hamid, T. Sato, D. Davar, M. K. Callahan +15 more
2022Annals of Oncology27 citations Open access
Semantic Scholar
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer
K. Moore, D. Hong, M. Patel, S. Pant +10 more
2021Targeted oncology27 citations
Semantic Scholar
NRG Oncology/RTOG 0848: Results after adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA).
Ross A. Abrams, K. Winter, K. Goodman, W. Regine +16 more
2024Journal of Clinical Oncology23 citations
Semantic Scholar
Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors
B. Perez, R. Aljumaily, T. Marron, M. Shafique +14 more
2024ESMO Open20 citations Open access
Semantic Scholar
MA04.01 Cemiplimab, a Human Monoclonal Anti-PD-1, Alone or in Combination with Radiotherapy: Phase 1 NSCLC Expansion Cohorts
V. Moreno, M. Gil-Martin, M. Johnson, R. Aljumaily +16 more
2018Journal of Thoracic Oncology18 citations Open access
Semantic Scholar
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma
A. Nassar, Chul Kim, T. Adeyelu, Elias J. Bou-Farhat +70 more
2025Nature Communications17 citations Open access
Semantic Scholar
Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort.
V. Moreno, P. Garrido, K. Papadopoulos, M. D. De Miguel Luken +9 more
2021Lung Cancer15 citations
Semantic Scholar
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer
Chao Li, L. Hart, T. Owonikoko, R. Aljumaily +11 more
2021Cancer Chemotherapy and Pharmacology15 citations Open access
Semantic Scholar
Immunologic and Tumor Responses of Pegilodecakin with 5-FU/LV and Oxaliplatin (FOLFOX) in Pancreatic Ductal Adenocarcinoma (PDAC)
J. Hecht, K. Papadopoulos, G. Falchook, M. Patel +17 more
2020Investigational new drugs14 citations Open access
Semantic Scholar
Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma
Amany R. Keruakous, A. Asch, R. Aljumaily, Daniel Zhao +1 more
2022Transplant Immunology13 citations Open access
Semantic Scholar
Pegilodecakin Combined With Pembrolizumab or Nivolumab for Patients With Advanced Solid Tumours (IVY): A Multicentre, Open-Label, Phase 1b Trial
A. Naing, D. Wong, J. Infante, R. Aljumaily
202113 citations
Semantic Scholar
Personalized Dosing Versus Fixed Dosing of Immune Checkpoint Inhibitors: A Cost Analysis Study.
S. Mukherjee, S. Ibrahimi, M. Machiorlatti, Darwin Roman +5 more
2018American Journal of Therapeutics13 citations
Semantic Scholar
A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
M. Johnson, M. Patel, R. Aljumaily, S. Jones +2 more
2023The Oncologist11 citations Open access
Semantic Scholar
Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data.
T. Owonikoko, K. Papadopoulos, M. Gil-Martin, V. Moreno +14 more
2018Annals of Oncology11 citations Open access
Semantic Scholar
Non-comparative, open-label, international, multicenter phase I/II study of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic merkel cell carcinoma (MCC) (CheckMate 358).
S. Bhatia, S. Topalian, W. Sharfman, T. Meyer +11 more
2023Journal of Clinical Oncology10 citations
Semantic Scholar
Effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan.
L. Hart, Z. Andrić, M. Hussein, R. Ferrarotto +16 more
2019Journal of Clinical Oncology10 citations
Semantic Scholar
Overall survival of PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).
J. Hecht, A. Naing, G. Falchook, M. Patel +12 more
201810 citations
Semantic Scholar
A phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors.
C. S. Denlinger, J. Infante, R. Aljumaily, A. Naing +14 more
2018Annals of Oncology10 citations Open access
Semantic Scholar
Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC).
N. Tannir, A. Naing, J. Infante, K. Papadopoulos +12 more
201810 citations
Semantic Scholar
INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumors.
E. Massarelli, A. Balmanoukian, M. Vieito, C. le Tourneau +14 more
20209 citations
Semantic Scholar
Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data.
T. Owonikoko, K. Papadopoulos, M. Johnson, M. Martín +15 more
20189 citations
Semantic Scholar
A phase I study of ATR inhibitor BAY1895344 (elimusertib) plus topotecan (ETCTN 10402): Results of dose escalation.
Shannon S. Stockton, Cathy Shyr, M. Cecchini, R. Aljumaily +10 more
2024Journal of Clinical Oncology7 citations
Semantic Scholar
Analysis of radiation therapy quality assurance in NRG Oncology RTOG 0848
L. Tchelebi, K. Winter, R. A. Abrams, H. Safran +14 more
2023International Journal of Radiation Oncology, Biology, Physics7 citations Open access
Semantic Scholar
488P Phase I trial of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in follicular lymphoma (FL), small cell lung cancer (SCLC) and castration-resistant prostate cancer (CRPC)
M. Schweizer, K. D. Penkov, A. Tolcher, A. Choudhury +15 more
2022Annals of Oncology7 citations Open access
Semantic Scholar
Phase I trial of the programmed death receptor 1 (PD-1) inhibitor, BI 754091, in patients (pts) with advanced solid tumors.
M. Johnson, M. Patel, L. Siu, M. Kozloff +9 more
20187 citations
Semantic Scholar
542P Ezabenlimab (BI 754091) monotherapy in patients (pts) with advanced solid tumours
M. Patel, M. Johnson, I. Winer, H. Arkenau +8 more
2021Annals of Oncology6 citations Open access
Semantic Scholar
Avelumab treatment for metastatic urothelial carcinoma in the phase Ib JAVELIN Solid Tumor Study: Updated safety and efficacy analysis with ≥ two years of follow-up.
A. Apolo, J. Ellerton, J. Infante, M. Agrawal +13 more
2019Journal of Clinical Oncology6 citations
Semantic Scholar
Abstract CT046: A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) inPIK3CA-mutated locally advanced or metastatic solid tumors
K. Jhaveri, D. Juric, C. Saura, A. Cervantes +14 more
2018Clinical Trials6 citations
Semantic Scholar
A phase 1b dose-escalation study of prexasertib, a checkpoint kinase 1 (CHK1) inhibitor, in combination with cisplatin in patients with advanced cancer.
M. Patel, D. Hong, J. Bendell, S. Jones +11 more
20186 citations
Semantic Scholar
Effect of body mass index and albumin level on outcomes of patients receiving anti PD-1/PD-L1 therapy.
S. Ibrahimi, S. Mukherjee, Darwin Roman, Caleb D. King +2 more
20186 citations
Semantic Scholar
A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort
Y. Chae, M. Othus, S. Patel, R. Aljumaily +13 more
2025Cancer Communications5 citations Open access
Semantic Scholar
647P EphA2-targeting bicycle toxin conjugate (BTC) BT5528 in patients (pts) with advanced solid tumors: A phase I/II study
E. Fontana, J.-S. Wang, M. Mckean, R. Aljumaily +13 more
2024Annals of Oncology5 citations
Semantic Scholar
A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced ccRCC.
Miso Kim, R. McDermott, Stephen Williamson, B. C. Cho +14 more
2024Journal of Clinical Oncology5 citations Open access
Semantic Scholar
Comparing the rate of immunotherapy treatment change due to toxicity by sex
K. Chua, Shane Kronstedt, Alain Kaldany, A. Srivastava +11 more
2024Cancer Reports5 citations Open access
Semantic Scholar
492TiP A phase I study of synthetic lethal, IDE397 (MAT2A inhibitor) as a monotherapy and in combination with chemotherapy in advanced solid tumors harboring MTAP deletion
M. Johnson, J. Rodón, R. Aljumaily, M. Villalona-Calero +14 more
2022Annals of Oncology5 citations Open access
Semantic Scholar
Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from phase 1 dose escalation and NSCLC Expansion Cohort.
V. M. García, E. Calvo, María Eugenia Olmedo García, M. Martín +10 more
20185 citations
Semantic Scholar
Adjuvant Chemotherapy +/− Chemoradiotherapy for Adenocarcinoma of The Pancreatic Head: Results of The Radiotherapy Randomization of NRG Oncology/RTOG 0848
Ross A Abrams, Kathryn A. Winter, K. Goodman, W. Regine +21 more
2026Journal of Clinical Oncology4 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Infante×9
Invite
J. Infante — researcher profile on SciRah
K. Papadopoulos×9
Invite
K. Papadopoulos — researcher profile on SciRah
M. Patel×9
Invite
M. Patel — researcher profile on SciRah
A. Naing×8
Invite
A. Naing — researcher profile on SciRah

×6

Invite

T. Owonikoko — researcher profile on SciRah

Invite

J. Bendell — researcher profile on SciRah

Invite

M. Fury — researcher profile on SciRah

A. Balmanoukian×5

Invite

A. Balmanoukian — researcher profile on SciRah

Invite

D. Wong — researcher profile on SciRah

An-Nie K. Hung×5

Invite

An-Nie K. Hung — researcher profile on SciRah

Invite

K. Mohan — researcher profile on SciRah

E. Stankevich×5

Invite

E. Stankevich — researcher profile on SciRah